Corpus ID: 22852235

A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.

@article{Woulfe1997APT,
  title={A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.},
  author={S. Woulfe and C. Bono and M. Zacheis and J. K. Welply and D. Kirschmann and T. Baudino and Y. Wang and D. A. Stone and G. Hanson and J. Vuletich and L. Bedell and B. Schwartz and S. Howard},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1997},
  volume={281 2},
  pages={
          663-9
        }
}
  • S. Woulfe, C. Bono, +10 authors S. Howard
  • Published 1997
  • Biology, Medicine
  • The Journal of pharmacology and experimental therapeutics
The ability of a peptidomimetic (SC-67655) to block the peptide binding site of the rheumatoid arthritis-linked human leukocyte antigen encoded by the DRB1*0401 allele was evaluated. The inhibitor bound to purified DRB1*0401 molecules with an affinity similar to that of the well-characterized peptide ligand HA307-319. Cell binding assays demonstrated that, in contrast to the promiscuous HA307-319 peptide, the peptidomimetic was highly specific for DRB1*0401. The inhibitor also blocked… Expand
Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules
TLDR
A heptapeptide with high affinity to rheumatoid arthritis–associated class II major histocompatibility (MHC) molecules is identified and peptidomimetic compounds of this type could find therapeutic use as MHC-selective antagonists of antigen presentation in the treatment of autoimmune diseases. Expand
Antigen-based T-cell-targeted immunotherapy: recent developments in autoimmunity and allergy
TLDR
Patent activity over the past 19 months in these fields in the light of new high affinity low molecular weight MHC class II restricted ligands and the design of inhibitors that block peptide binding to MHC molecules has experienced a renewal of interest. Expand
Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy.
TLDR
Rational design of modified peptides for immunotherapy has to await further insights into the relationships between structure and peptide/peptidomimetic induced T cell activation, and until that, there is no possibility to take advantage of the tailor made origin of peptidomIMetics. Expand
From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins.
TLDR
The design and biological properties of the very first nonpeptide ligands of major histocompatible proteins as well as their potential application in vaccination, Major Histocompatibility Complex (MHC) blockade or T cell receptor antagonism are reviewed. Expand
Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids.
TLDR
It is concluded that the side chain position as well as the backbone nitrogen atom hydrogen bonding features of solvent-exposed residues in the peptide can be important for MHC binding affinity. Expand
Peptide-based therapies for arthritis
TLDR
This review highlights strategies aimed at interfering with the immune synapse in the treatment of inflammatory arthritis and discusses peptide and peptidomimetic-based approaches used to develop transmembrane peptides. Expand
Modified Glycopeptides Targeting Rheumatoid Arthritis : Exploring molecular interactions in class II MHC/glycopeptide/T-cell receptor complexes
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that leads to degradation of cartilage and bone mainly in peripheral joints. In collagen-induced arthritis (CIA), a mouse model for RExpand

References

SHOWING 1-10 OF 38 REFERENCES
Cellular mechanisms of exogenous peptide binding to HLA class II molecules in B cells.
TLDR
The data suggest that the APC are endowed with cellular mechanisms that increase the efficiency of both the loading and the unloading of Class II HLA with exogenous peptides, which do not appear to require ATP or to involve newly synthesized Class II molecules, intracellular acidic compartments, or the microtubule-microfilament system. Expand
The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues.
TLDR
Low concentrations of Au(I)TM led to a markedly reduced IL-2 release of T cell hybridoma clones that recognized peptides containing two or more cysteine (Cys) residues, such as bovine insulin A1-14, which might contribute to the therapeutic effect of Au (I) compounds in rheumatoid arthritis. Expand
Promiscuous and allele-specific anchors in HLA-DR-binding peptides
The major histocompatibility complex (MHC) class II molecules are highly polymorphic membrane glycoproteins that bind peptide fragments of proteins and display them for recognition by CD4+ T cells.Expand
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.
TLDR
Results suggest that Cop 1 indeed competes with BP for MHC binding and, thereby, inhibits T-cell responses to BP, and may indicate its potential as a broad-spectrum drug for multiple sclerosis. Expand
Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.
TLDR
Synthetic peptides, corresponding to endogenous peptide sequences, bound with high affinity to the HLA-DR molecules from which they were eluted, but an invariant chain peptide was eluted from the DRB1*0402 molecules but not from the RA-associated molecules, which may contribute to the loading of autoantigen peptides into these molecules and to their association with disease. Expand
Characterization of the specificity of peptide binding to four DR haplotypes.
This study describes the establishment of a peptide-binding assay for purified, detergent-solubilized DR molecules. For each of the DR specificities and peptides studied, a unique pattern ofExpand
Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation
TLDR
Supporting background provides the underlying basis for the theory that antimalarials may act to prevent autoimmunity by the following putative mechanism. Expand
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
TLDR
Most of the peptides derived from endogenous proteins that intersect the endocytic/class II pathway, even though class II molecules are thought to function mainly in the presentation of exogenous foreign peptide antigens, were derived from major histocompatibility complex-related molecules. Expand
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions.
TLDR
Using two different peptide ligands as model systems, it is demonstrated how the fine allelic specificity of the DR binders can be predictably modulated by introducing subtle changes in the primary amino acid sequence. Expand
Peptide competition for antigen presentation.
TLDR
It is shown that it is possible to modulate T-cell activation by interfering with the binding of antigenic peptides to MHC class II molecules, which could represent a suitable approach to a rational treatment of autoimmune diseases and, possibly, of allograft rejection. Expand
...
1
2
3
4
...